Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre

Current Oncology

View Publication Info
 
 
Field Value
 
Title Lysine analogue use during cancer surgery: a survey from a Canadian tertiary care centre
 
Creator Montroy, J.
Hutton, B.
Fergusson, D.A.
Tinmouth, A.
Lavallée, L.T.
Cagiannos, I.
Morash, C.
Flaman, A.
Breau, R.H.
 
Subject surgery
thrombosis
lysine analogues
tranexamic acid
surveys
 
Description Background When used during surgery, antifibrinolytic hemostatic agents such as lysine analogues are effective at reducing blood loss and the need for transfusions. Despite proven efficacy, use of hemostatic agents remains low during some surgeries. Our objective was to explore surgeon opinions about, and use of lysine analogues in, oncologic surgeries at a large tertiary care academic institution.
Methods We administered a survey to surgeons who perform high-transfusion-risk oncologic surgeries at a large academic hospital in Ottawa, Ontario. Design and distribution of the survey followed a modified Dillman method. To ensure that the survey questionnaire was relevant, clear, and concise, we performed informant interviews, cog­nitive interviews, and pilot-testing. The final survey consisted of 19 questions divided into 3 sections: respondent demographics, use of hemostatic agents, and potential clinical trial opinions.
Results Of 28 surgeons, 24 (86%) participated. When asked to indicate the frequency of lysine analogue use, “never” accounted for 46% of the responses, and “rarely” (<10% of the time) accounted for 23% of the responses. Reasons for never using included “unfamiliar with benefits” and “prefer alternatives.” Fifteen surgeons (63%) felt that a trial was needed to demonstrate the efficacy and safety of lysine analogues in their cancer field.
Conclusions Our survey found that lysine analogues are infrequently used during oncologic surgeries at our institution. Many surgeons are unfamiliar with the benefits and side effects of lysine analogues and, alternatively, use topical hemostatic agents. Our results demonstrate that future trials exploring the efficacy and safety of lysine analogues in oncologic surgery are needed.
 
Publisher Multimed Inc.
 
Date 2020-08-06
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/6613
10.3747/co.27.6613
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/6613/9633
http://www.current-oncology.com/index.php/oncology/article/view/6613/9697
 
Rights Copyright (c) 2020 Current Oncology
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library